PREDICATE Trial For Respiratory Tract Infections

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

December 8, 2027

Study Completion Date

December 8, 2028

Conditions
Respiratory Tract Infections
Interventions
DRUG

Prednisolone 30 mg

This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.

DRUG

Placebo

This a tablet identical to prednisolone.

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER